Abstract
Gabapentin and pregabalin are anticonvulsant drugs that are also utilized for pain management. A mass spectrometry method was developed and validated to quantify gabapentin and pregabalin in urine to support testing for adherence.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Dougherty JA, Rhoney DH (2001) Gabapentin: a unique anti-epileptic agent. Neurol Res 23:821–829
Ettinger AB, Argoff CE (2007) Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4:75–83
Krasowski MD, McMillin GA (2014) Advances in anti-epileptic drug testing. Clin Chim Acta 436:224–236
Chang CY, Challa CK, Shah J, Eloy JD (2014) Gabapentin in acute postoperative pain management. Biomed Res Int 2014:631756
Goa KL, Sorkin EM (1993) Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 46:409–427
McLean MJ (1995) Gabapentin. Epilepsia 36(Suppl 2):S73–S86
Beydoun A, Uthman BM, Sackellares JC (1995) Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 18:469–481
Taylor CP, Angelotti T, Fauman E (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73:137–150
Shneker BF, McAuley JW (2005) Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 39:2029–2037
Tassone DM, Boyce E, Guyer J, Nuzum D (2007) Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29:26–48
Zareba G (2005) Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today 41:509–516
Guglielmo R, Martinotti G, Clerici M, Janiri L (2012) Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther 29:947–957
Buoli M, Caldiroli A, Serati M (2017) Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. Expert Opin Drug Metab Toxicol 13:351–359
Hamandi K, Sander JW (2006) Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 15:73–78
Blommel ML, Blommel AL (2007) Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 64:1475–1482
Schulze-Bonhage A (2013) Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol 9:105–115
Heltsley R, Depriest A, Black DL, Robert T, Caplan YH, Cone EJ (2011) Urine drug testing of chronic pain patients. IV. Prevalence of gabapentin and pregabalin. J Anal Toxicol 35:357–359
Acknowledgments
The authors would like to thank the ARUP Institute for Clinical and Experimental Pathology for support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Merrigan, S., Johnson-Davis, K.L. (2019). Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method to Quantify Gabapentin and Pregabalin in Urine. In: Langman, L., Snozek, C. (eds) LC-MS in Drug Analysis. Methods in Molecular Biology, vol 1872. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8823-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8823-5_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8822-8
Online ISBN: 978-1-4939-8823-5
eBook Packages: Springer Protocols